Business context and reporting period
This is BioSante Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2011—not an ANI Pharmaceuticals filing, despite the request metadata. BioSante focused on specialty pharmaceuticals, with LibiGel in Phase III development and Elestrin marketed in the U.S. by a licensee. Other programs included Bio-T-Gel, cancer vaccines and a contraceptive candidate.
Financial results and position
| Metric | Q2 2011 / June 30, 2011 | Comparison |
|---|---|---|
| Revenue | $81,003 | Q2 2010: none; H1 2011: $138,003 vs. $2.28 million in H1 2010 |
| Net loss | $14.98 million | Q2 2010: $10.79 million; H1 2011: $32.23 million vs. $21.33 million |
| Loss per share | $0.16 | Q2 2010: $0.17; H1 2011: $0.36 vs. $0.35 |
| Research and development | $11.12 million | Q2 increased 28%; H1 was $25.98 million, up 44% |
| General and administration | $1.99 million | Q2 increased 29%; H1 was $3.58 million, up 8% |
| Cash and cash equivalents | $37.13 million | $38.16 million at Dec. 31, 2010 |
| Total assets / liabilities | $42.76 million / $31.23 million | At Dec. 31, 2010: $44.77 million / $25.62 million |
| Stockholders’ equity / accumulated deficit | $11.53 million / $197.86 million deficit | Equity was $19.15 million and deficit $165.63 million at Dec. 31, 2010 |
| Cash flows, H1 | Operating use: $24.36 million; investing use: $0.54 million; financing inflow: $23.88 million | Operating use was $15.04 million in H1 2010 |
Revenue was minimal and primarily consisted of Elestrin royalties, offset by a corresponding Antares royalty obligation. BioSante reported no operating profit; losses reflect its development-stage cost base. The filing does not provide a clear gross-margin measure.
Material changes versus the prior comparable period
- H1 revenue fell 94%, principally because H1 2010 included licensing-related revenue associated with the amended Elestrin agreement; 2011 revenue was limited to royalties.
- H1 R&D costs increased $7.90 million, mainly due to the three LibiGel Phase III trials. The net loss rose 51%.
- Operating cash use increased by $9.32 million year over year. March 2011 equity financing provided $23.86 million net, while cash declined by $1.03 million over H1.
- Convertible notes had $22.0 million stated principal and $20.94 million recorded fair value at June 30. A $2.39 million H1 fair-value adjustment increased expense; this is a noncash accounting item. The notes bear 3.125% interest, with $1.23 million principal due November 2011 and $20.78 million due May 2013.
- Common shares outstanding increased from 81.4 million at year-end to 93.6 million at June 30. A subsequent August offering issued 16.0 million additional shares.
Outlook, commentary and risks
- Management expected June-end cash plus approximately $45.0 million net proceeds from the August 2 offering to fund liquidity needs for at least 18 months, while cautioning that estimates could prove incorrect. It expected continuing substantial losses for at least 18–24 months.
- Management projected LibiGel R&D spending of $3–4 million per month through completion of the two efficacy trials, expected in Q4 2011, then $2–3 million per month. It targeted an NDA submission by year-end 2012.
- LibiGel efficacy-trial enrollment was complete in Q1 2011; enrollment in the cardiovascular and breast-cancer safety study was completed in May. That study was to continue for 12 months of therapy after the final enrollee for primary analysis, with longer-term follow-up continuing through 2016.
- The August equity offering strengthened liquidity but increased dilution. The Kingsbridge equity facility, available through December 2011 subject to conditions and at an 8–14% discount, had not been used as of June 30. No credit facility was in place.
- Key risks include clinical results and FDA approval, trial timing and cost, ability to secure partners or further capital, sustained losses, reliance on licensors/licensees and third-party manufacturers, and uncertain commercialization and reimbursement. FDA Special Protocol Assessments do not guarantee approval.
- Abbott filed a patent-infringement complaint against Teva concerning Bio-T-Gel in April 2011. Teva was defending the matter; the filing said it could delay approval or launch and affect potential royalties. BioSante’s Legal Proceedings section otherwise says “Not applicable.”
- The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no material change in contractual obligations since year-end and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is BioSante Pharmaceuticals, Inc., not ANI Pharmaceuticals, Inc.
- Track LibiGel trial analyses, safety findings, FDA interactions and whether the NDA timetable and estimated spending remain achievable.
- Assess actual cash burn and runway against management’s 18-month estimate, including the use of August offering proceeds and any additional financing needs.
- Review the dilution and potential share issuance from the August offering, March warrants, options and convertible notes.
- Monitor the November 2011 note maturity and the Abbott–Teva Bio-T-Gel patent litigation and its regulatory/commercial impact.